New Takeda India Leadership Amid Realignment
This article was originally published in PharmAsia News
Whether or not it's a rejig in the normal course of business isn't very clear, but Japanese pharma giant Takeda has "realigned" certain teams as it pursues plans to provide sustainable access to its medicines under a new leadership in India.
You may also be interested in...
Will Takeda take a less measured approach in India, where Shire brings it a significant on-market portfolio? Scrip outlines the current shape of things in the promising but complex emerging market as the two companies head towards combining forces globally.
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.